Bristol Myers Squibb stock saw its IBD SmartSelect Composite Rating jump to 96 Friday, up from 94 the day before. The drug giant sports a 85 Relative Strength Rating.
The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The best stocks tend to have a 95 or better grade as they kick off a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Looking For Winning Stocks? Try This Simple Routine
Is Bristol Myers Squibb Stock A Buy?
Bristol Myers Squibb is trading within the buy zone from a 65.95 entry from a cup with handle. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The drug stock sports a 94 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 94% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
Earnings Growth Keeps Trekking
In Q4, the company posted 25% earnings growth. That means it's now generated three straight quarters of rising EPS growth. Top line growth came in at 8%, down from 10% in the prior quarter.
Bristol-Myers Squibb stock holds the No. 1 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie and Pfizer are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharma Industry And Stock News."
